SHR-1701 + carboplatin + paclitaxel

SHR-1701 + carboplatin + paclitaxel is a combination therapy being investigated for various cancer types, particularly cervical cancer. This combination consists of SHR-1701 (a novel bifunctional fusion protein) along with two chemotherapy agents (carboplatin and paclitaxel). SHR-1701 is a bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor II[1][5]. This dual-targeting approach aims to simultaneously block the PD-1/PD-L1 immune checkpoint pathway while neutralizing TGF-β signaling, potentially enhancing antitumor immune responses. The combination with carboplatin (a platinum-based chemotherapy agent) and paclitaxel (a taxane) creates a regimen that targets cancer through multiple mechanisms - immune modulation via SHR-1701 and direct cytotoxicity via the chemotherapy agents. This combination has shown promising results in clinical trials, particularly for cervical cancer. In a phase 1b study for persistent, recurrent, or metastatic cervical cancer, the combination demonstrated a 77.4% objective response rate (ORR) and a 93.5% disease control rate (DCR)[5]. The 6-month progression-free survival rate was 93.5%[5]. The combination has also been studied in esophageal squamous cell carcinoma (ESCC), where it was combined with radiotherapy in the neoadjuvant setting. In this context, the regimen achieved a pathological complete response rate of 30.0% in patients who underwent surgery[2]. The safety profile of SHR-1701 + carboplatin + paclitaxel appears manageable. Treatment-related adverse events occur in most patients, but they are predominantly grade 1-2 in severity[5]. In cervical cancer trials, the combination has demonstrated a "manageable safety profile" alongside its "potent antitumor activity"[5]. This combination represents an emerging approach in oncology that combines immunotherapy with conventional chemotherapy to potentially enhance efficacy beyond what either approach could achieve alone.

Other names

PC (for paclitaxel + carboplatin)CarboTaxol (for paclitaxel + carboplatin)